These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10589369)

  • 1. Combination therapy with DMARDs and biological agents in collagen-induced arthritis.
    Williams RO; Malfait AM; Butler DM; Walmsley MJ; Feldmann M; Maini RN
    Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S115-20. PubMed ID: 10589369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell cycle regulation therapy combined with cytokine blockade enhances antiarthritic effects without increasing immune suppression.
    Hosoya T; Iwai H; Yamaguchi Y; Kawahata K; Miyasaka N; Kohsaka H
    Ann Rheum Dis; 2016 Jan; 75(1):253-9. PubMed ID: 25165034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination biologic therapy.
    Isaacs JD; Morgan AW; Strand V
    Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S121-4. PubMed ID: 10589370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effect of enzyme therapy and combination therapy with cyclosporin A on collagen-induced arthritis.
    Rovenská E; Svík K; Stancíková M; Rovenský J
    Clin Exp Rheumatol; 2001; 19(3):303-9. PubMed ID: 11407084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms.
    Bartelds GM; Wijbrandts CA; Nurmohamed MT; Wolbink GJ; de Vries N; Tak PP; Dijkmans BA; Crusius JB; van der Horst-Bruinsma IE
    Arthritis Rheum; 2009 Aug; 60(8):2541-2. PubMed ID: 19644871
    [No Abstract]   [Full Text] [Related]  

  • 6. Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram.
    Ross SE; Williams RO; Mason LJ; Mauri C; Marinova-Mutafchieva L; Malfait AM; Maini RN; Feldmann M
    J Immunol; 1997 Dec; 159(12):6253-9. PubMed ID: 9550429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
    Cohen SB
    Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?
    Bendtzen K
    Arthritis Rheum; 2011 Apr; 63(4):867-70. PubMed ID: 21452309
    [No Abstract]   [Full Text] [Related]  

  • 9. [B cell depletion therapy using anti-CD20 antibodies in rheumatoid arthritis].
    Yukawa N; Mimori T
    Clin Calcium; 2007 Apr; 17(4):569-76. PubMed ID: 17404487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of combination second-line or disease-modifying antirheumatic drug therapy in rheumatoid arthritis.
    Williams HJ
    Br J Rheumatol; 1995 Nov; 34 Suppl 2():96-9. PubMed ID: 8535657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody.
    Fischer JA; Hueber AJ; Wilson S; Galm M; Baum W; Kitson C; Auer J; Lorenz SH; Moelleken J; Bader M; Tissot AC; Tan SL; Seeber S; Schett G
    Arthritis Rheumatol; 2015 Jan; 67(1):51-62. PubMed ID: 25303306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mechanism of action of biological disease--modifying antirheumatic drugs].
    Takahashi N; Ishiguro N
    Nihon Rinsho; 2016 Jun; 74(6):882-6. PubMed ID: 27311173
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Tijhuis GJ; van de Putte LB; Breedveld FC
    Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study into the mechanisms of action of anti-tumor necrosis factor alpha, anti-CD4, and combined anti-tumor necrosis factor alpha/anti-CD4 treatment in early collagen-induced arthritis.
    Marinova-Mutafchieva L; Williams RO; Mauri C; Mason LJ; Walmsley MJ; Taylor PC; Feldmann M; Maini RN
    Arthritis Rheum; 2000 Mar; 43(3):638-44. PubMed ID: 10728758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis.
    Kubota T; Nii T; Nanki T; Kohsaka H; Harigai M; Komano Y; Sugihara T; Nonomura Y; Hirose W; Nagasaka K; Sakurai T; Miyasaka N
    Mod Rheumatol; 2007; 17(6):531-3. PubMed ID: 18084712
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-interleukin-6 therapy in rheumatoid arthritis.
    Woodrick R; Ruderman EM
    Bull NYU Hosp Jt Dis; 2010; 68(3):211-7. PubMed ID: 20969554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study.
    Finckh A; Dehler S; Gabay C;
    Ann Rheum Dis; 2009 Jan; 68(1):33-9. PubMed ID: 18230627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy in mice: what can we learn that may be useful for understanding rheumatoid arthritis?
    Williams RO
    Springer Semin Immunopathol; 1998; 20(1-2):165-80. PubMed ID: 9836375
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples.
    Combe B; van Vollenhoven R
    Ann Rheum Dis; 2013 Sep; 72(9):1433-5. PubMed ID: 23625979
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.